Home Newsfeeds Exane BNP Paribas Downgrades Chevron to Underperform

Exane BNP Paribas Downgrades Chevron to Underperform

Exane BNP Paribas analyst Lucas Herrmann downgrades Chevron (NYSE:CVX) from Neutral to Underperform.

byBenzinga Newsdesk

December 14, 2022

1 minute read

Exane BNP Paribas analyst Lucas Herrmann downgrades Chevron (NYSE:CVX) from Neutral to Underperform.

Bogota Finl Q4 EPS $0.14 Misses $0.15 Estimate

By Michael Horton

January 30, 5:46 PM

Bogota Finl (NASDAQ:BSBK) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.15 by 6.67 percent. This is unchanged from the same period last year.

BSBK

Vaxxinity CEO Mei Mei Hu Speaking At White House Summit On Future of COVID-19 Vaccines

By Benzinga Newsdesk

July 25, 11:58 AM

Vaxxinity, Inc. (NASDAQ:VAXX) Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines. Hu is honored by the invitation and eager to engage in

VAXX

News

Akso Health Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

By Michael Horton

October 28, 4:11 PM

Akso Health Group (NASDAQ:AHG) ("Akso Health" the "Company" or "we"), today announced that the Company has received a written notification (the "Notification Letter") from the

AHG

PharmaCielo FY 2022 Revenue Grows 173%, What About Adjusted EBITDA?

By Vuk Zdinjak

May 1, 8:44 AM

PharmaCielo Ltd. (OTCQX: PCLOF) (TSXV:PCLO) released financial results for the fourth quarter and year ended December 31, 2022, revealing total revenue of CA$5.3 million ($3.9 million), an increase of 173% compared to CA$1.9 million in FY 2021.

PCLOF

Exane BNP Paribas Downgrades Chevron to Underperform

Related Posts

Bogota Finl Q4 EPS $0.14 Misses $0.15 Estimate

Vaxxinity CEO Mei Mei Hu Speaking At White House Summit On Future of COVID-19 Vaccines

Akso Health Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

PharmaCielo FY 2022 Revenue Grows 173%, What About Adjusted EBITDA?